SUMMARY Twenty patients with severe symptomatic Paget's disease were treated with a series of 15 mg intravenous infusions of 3-amino-l-hydroxypropylidene-1,1-bisphosphonate (APD). A regimen of either five consecutive days of treatment (regimen 1) or a course of 12 weekly infusions was administered (regimen 2). In five cases regimen 2 followed regimen 1 after a three month interval. Alkaline phosphatase levels fell in all patients and returned to the normal range in 12. All but one of the patients obtained symptomatic improvement. There was a median fall in alkaline phosphatase activity of 63%. Eight patients observed a transient increase in bone pain starting about 24 hours after the first infusion. Intravenous APD was well tolerated, and we conclude that it is an effective treatment for Paget's disease; this route of administration avoids the problem of poor and unpredictable gastrointestinal absorption seen when a bisphosphonate is given orally. The optimal dose and duration of APD therapy, frequency of relapse, requirement for further courses, and merits relative to other second generation bisphosphonates remain to be established.
For over 15 years the principal treatment for Paget's disease of bone has been synthetic salmon or porcine calcitonin. This therapy, which has to be given by injection two or three times a week, may produce unacceptable side effects, including nausea, flushing, and febrile reactions, in up to 12% of patients.' Another potential problem is the development of resistance, which is at least partly related to the development of antibodies.2 The cytotoxic antibiotic, mithramycin, has also been used3 4 
Results
The fall in alkaline phosphatase levels is detailed in Table 1 , the mean pretreatment level was 690 IU/I (range 161-3775) and mean post-treatment level 276 IU/I (range 43-2710). These results are shown in Fig. 1 . As expected,"' 15 changes in alkaline phosphatase were preceded by a fall in the hydroxyproline/creatinine ratio (data not shown). Individual charts are shown for four patients in Fig.  2 , which also show changes in alkaline phosphatase during and after previous treatments. Fig. 3 shows the response in the only patient treated who had osteoporosis circumscripta. As early as three months after the end of the course of therapy with regimen 2 there was a dramatic degree of remineralisation and marked reduction in activity on the bone scan (Fig. 4) .
The treatment was well tolerated by all patients, but eight complained of a transient exacerbation of pain after the first injection. One claimed to experience headaches both during and after each (Table 1) . Although no objective assessment was made of symptomatic response in the first 14 patients, 12 of the 13 patients with pain reported a marked improvement. All six of the patients in the formal study showed an improvement in pain, which was assessed with a visual analogue scale. All patients have been followed up, and six have remained in remission for a mean of 11 months (range 9-14). Twelve patients have been retreated, three with a single 30 mg infusion and nine with a further course of intravenous APD, and another patient is currently awaiting retreatment. One patient (No 10), with partial fractures and severe bone pain, had a tibial osteotomy five months after a second course of APD. A further course of treatment, delayed for three months after surgery, has not led to a further decline in alkaline phosphatase.
One patient (No 9) developed severe pain with increased size of a longstanding fissure fracture of the femoral shaft six months after stopping treatment.
Discussion
Our findings indicate that even a short course of low dose intravenous APD can produce a marked biochemical and clinical response in Paget's disease APD for the treatment of Paget's disease 1017 of bone. In 12 of the patients alkaline phosphatase concentrations returned to within the normal range (30-130 IU/l) after treatment with intravenous APD. These patients all had less than 11 bones affected (bone scan score <11), and all had an initial alkaline phosphatase level of less than 600 IUll. A further three patients had bone scan scores of less than 11 but also had initial alkaline phosphatase levels of 688, 845, and 815 IU/I respectively, which fell, but not to within the normal range, after treatment. In the present study we administered the same dose of APD to all patients irrespective of weight and extent of Paget's disease. APD is rapidly cleared from the blood and taken up into bone, especially at sites of resorption,16 and the half life of bone retention will probably depend on the bone turnover rate. It may well be that patients with very extensive disease require a larger dose to achieve the same degree of uptake into affected bones. This is currently the subject of further study. Fig 2 shows 18 Earlier studies in rats showed that EHDP led to hyperphosphataemia, which was postulated to result from competitive inhibition of renal tubular secretion of phosphate by the diphosphonate. In contrast, our finding of mild hypophosphataemia after APD confirms the results of Heynen et al. 10 Although we did not detect any significant reduction in plasma calcium concentration, it is likely that this occurred transiently due to the inhibitory effect of the diphosphonate on bone resorption. This would lead to an increase in plasma parathyroid hormone concentration and hence account for the subsequent hypophosphataemia. In all six subjects in whom the phosphate concentrations fell to <0-8 mmol/l the values returned to within the normal range, either during or after discontinuation of treatment.
We believe that the intravenous route of administration of bisphosphonates has two potential advantages over the oral route. Firstly, for reasons that are not clear, absorption of oral diphosphonate varies as much as 10-fold between individuals,'9 and is of course totally inhibited by food. Secondly, it should be possible to distinguish between genuine resistance to bisphosphonates and apparent resistance due to failure of absorption, and to make adjustments to the dose with less risk of toxic effects.
